Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. - Wikidata - awgldk - TriplyDB

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

http://www.wikidata.org/entity/Q40390348

about

Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death Therapeutic microRNA strategies in human cancer Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside Nanotechnology: Future of Oncotherapy Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives Delivery of gene silencing agents for breast cancer therapy Nanotechnology in cancer therapy miRNA Deregulation in Cancer Cells and the Tumor Microenvironment The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment Preclinical and clinical development of siRNA-based therapeutics The ZNF304-integrin axis protects against anoikis in cancer Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems Therapeutic use of microRNAs in lung cancer Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression Identification of novel therapeutic targets in microdissected clear cell ovarian cancers Neuropilin-2 mediated β-catenin signaling and survival in human gastro-intestinal cancer cell lines IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs Chemical modification: the key to clinical application of RNA interference?Advances in Systemic siRNA Delivery Optical imaging-guided cancer therapy with fluorescent nanoparticles MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine.Cationic lipid nanodisks as an siRNA delivery vehicle EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis Hematogenous metastasis of ovarian cancer: rethinking mode of spread.Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.Eph receptors and ephrins in cancer: bidirectional signalling and beyond.Targeted gene silencing using RGD-labeled chitosan nanoparticles.Regulation of tumor angiogenesis by EZH2.Prognostic biomarkers in ovarian cancer.

P2860

Q24632721-4CBF60A9-26FB-4418-A20C-A131718060E8 Q24651333-23AEB019-7D49-4EA6-A8C1-0EFACBF6BCBF Q26741449-A465838B-D62D-4A7D-A32F-A1CD461DAFEF Q26801067-8CCBBFE5-F8C8-4FEC-BC39-E6D2D3BAD2AA Q26859021-EDC19441-BB87-4A69-85FB-B94C67DD9862 Q27008706-8F6EE1A1-3A4B-4C6D-AD48-3DF9D83CC349 Q27023013-C29CF37D-4E4A-4DBF-B8FE-73B2230ED26D Q27025496-9B3DE8B7-0E67-4A18-8051-917711D488B6 Q27339492-0AC7ACBE-3E90-488F-B013-329B07EBCC5F Q28085290-6D1B5DF3-74DE-4416-81EC-A6458B4AA16D Q28115264-D3DDD640-3042-4EE9-80CE-D9627CB2C23A Q28257114-448F0A25-1CA2-4A98-9DB0-F72FECF78821 Q28271388-DD928F7C-4599-42EB-9DFD-B42A5E8030F1 Q28307739-2ED8D285-387D-4EDB-A768-351B21340715 Q28395046-DEDC598F-C25D-4866-8A85-5677DCB36674 Q28395179-661E744E-FFAF-4108-9D2D-A61257A548D9 Q28609305-A2CF5FBE-8B10-471B-9998-9C4E80C161CF Q28611264-A6D9AD4A-F7BA-4605-9C30-7BECDC87CF28 Q28742873-E7397797-1D2E-4EB1-8C79-8F677AF76CED Q28743682-93A28AE5-B2D3-4822-AB46-7E358D3AA798 Q30355682-1EAAC24E-1087-4FC6-A719-9DED9C3C011C Q30405442-35F497A4-B3AF-436E-A500-970C27B4355D Q30480823-64AC6A55-F4D8-41E5-8291-F46B5348A912 Q30483685-72C36CB9-5ED2-4109-911D-C321D082595A Q30541608-62E3AE7D-D0E2-4B62-B7D5-8FA114A67DD9 Q30844815-3CC7F71E-69C4-43B6-AEDB-87E04C46190B Q33308712-507A3C09-DB54-486A-8633-ABE1D65F6FC6 Q33613316-37AC428B-7A6F-4E6A-84EA-92864DA40693 Q33731037-2B8CA2D9-3645-4523-9148-4057A3400213 Q33733403-B7DC4D87-87E1-4FD2-A662-6CEF1EB25647 Q33745473-1BBE7008-00D7-42C8-AB1C-EA354C17E8CB Q33778507-7BF4DB17-C861-4191-815E-54B09DC579CE Q33815723-14E7DC99-7271-47BA-BFE3-3090AF87F3A7 Q33908024-B811DE63-F523-475C-B772-2194B47EE4FA Q33935474-DEBA7F39-B467-4798-B6B3-40D0D9D541F9 Q33956803-BC240377-67F9-4D2A-8C5C-5AB84F95C79D Q34021365-6925DAD0-031B-4D03-9D86-39BB3E202DA9 Q34031859-B59AC3E6-16C3-4DDE-8E56-B182CFCF0BDB Q34073170-9F8ACBE7-014A-428F-8478-FC3E09F4FF6E Q34086636-D9D07B05-39E5-4FF7-847D-90E6941881C5

P2860

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

http://www.wikidata.org/entity/Q40390348

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Therapeutic EphA2 gene targeti ...... mall interfering RNA delivery.

@en

type

label

Therapeutic EphA2 gene targeti ...... mall interfering RNA delivery.

@en

prefLabel

Therapeutic EphA2 gene targeti ...... mall interfering RNA delivery.

@en

P1433

Q40390348-130DA966-93E6-44A3-BE90-1C1FBE46ADAC

P1476

Q40390348-18640B15-C4C0-46CE-983E-136CF4AA9E01

P2093

Q40390348-28A55BB5-E36F-4155-AFE5-27E2BD8EB033

Q40390348-3BFD5D13-7DB8-4156-8C03-9903E130CB9A

Q40390348-83396DC7-6E03-4AC8-8261-122C4410BE38

Q40390348-9BCE40B6-F27D-4B40-BE26-844844CB5B44

Q40390348-C2864FDF-69C6-4012-8B75-4BF464B911FA

Q40390348-C8746CE4-67DC-48FE-99C6-1D6B11B2B837

Q40390348-FB9262FB-1C79-458F-A508-A6874D5235CA

P304

Q40390348-6D38E9AC-629E-430A-A632-832BC9091F41

P31

Q40390348-C7FC4620-2C53-450F-A754-EA055DB5789E

P356

Q40390348-A6A92E26-5B9E-4005-86FF-C3AC18B30075

P407

Q40390348-0D288DE5-802C-4201-A924-DBBCDC792883

P433

Q40390348-63A74FD0-8168-449A-80B2-19BFE0844579

P478

Q40390348-CA3764C3-2256-4DD8-B428-D6F1A4177BEC

P577

Q40390348-7D0DF700-7E25-4767-AACC-11C88FE568C9

P698

Q40390348-252F176B-0ABB-452D-81E4-8FC93B9F3252

P356

0008-5472.CAN-05-0530

P1433

Cancer Research

P1476

Therapeutic EphA2 gene targeti ...... mall interfering RNA delivery.

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Arturo Chavez-Reyes

http://www.w3.org/2001/XMLSchema#string

Charles N Landen

http://www.w3.org/2001/XMLSchema#string

Corazon Bucana

http://www.w3.org/2001/XMLSchema#string

Gabriel Lopez-Berestein

http://www.w3.org/2001/XMLSchema#string

Michael T Deavers

http://www.w3.org/2001/XMLSchema#string

Rosemarie Schmandt

http://www.w3.org/2001/XMLSchema#string

P304

6910-6918

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-05-0530

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16061675

http://www.w3.org/2001/XMLSchema#string